Showing posts with label Patients. Show all posts
Showing posts with label Patients. Show all posts

Monday, April 11, 2011

Seniors Group Asks Medicare Part-D Plans To Provide Affordable Gout Medication For Patients


Main Category: Medicare / Medicaid / SCHIP
Also Included In: Gout
Article Date: 25 Feb 2011 - 2:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
5 starsnot yet rated
As part of the 60 Plus Association's "Keeping Seniors Safe" project, the organization's chairman, Jim Martin, recently sent letters to the CEOs of five Part-D Medicare plans, urging them to provide accessible colchicine-based medications to gout patients after untested and potentially harmful options were removed from the marketplace as part of an important Food and Drug Administration (FDA) safety-initiative.

"In light of the FDA's removal of unapproved colchicine from the market, [these outlying companies] must follow the lead of other Part-D insurers around the country and reclassify COLCRYS as a tier-1 or 2 drug to ensure seniors have access to their vital gout medications" Martin wrote to the CEOs of the companies. "It is unjust to force patients to suffer through often excruciatingly-painful acute gout flare-ups despite the fact that they were promised affordable coverage for their medications."

The FDA's "Unapproved Drugs Initiative" calls for the removal of unapproved drugs from the market when approved versions exist. The agency recently acted on this initiative by removing untested colchicine products from the market.

"The FDA did what was best for patients by removing untested colchicine products from the market," wrote Martin. "We hope your company will also act in the best interest of patients and immediately work to ensure that seniors enrolled in your Part-D plan have access to the colchicine products they were promised-and sorely need."

In addition to the CEOs of offending insurance companies, copies of Martin's letter were sent to Secretary of Health and Human Services Kathleen Sebelius, HHS Deputy Secretary William Corr, CMS Administrator Donald Berwick, Senator Bill Nelson (D-FL), Representative Pete Stark (D-CA), Representative Nancy Pelosi (D-CA), Representative Henry Waxman (D-CA), Senator Chuck Schumer (D-NY), Senator Sherrod Brown (D-OH), Senator Robert Menendez (D-NJ), Senator John Cornyn (R-TX), and Representative Allyson Schwartz (D-NY).

Source:
60 Plus Association

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

posted by Gregg on 25 Feb 2011 at 9:36 am

Where the article is mistaken is in saying that the former versions of Colchicine were "potentially harmful". There is nothing different chemically about Colcrys, it merely has different labeling. For the privilege of getting this new "special" label on the package, the FDA says you must pay one-hundred and fifty dollars (or more) a month, instead of the previous twenty dollars or so.

| post followup | alert a moderator |


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Saturday, April 9, 2011

Periocular Treatment Improves Eye Comfort And Quality Of Life For Patients With Facial Paralysis


Academic Journal
Main Category: Eye Health / Blindness
Also Included In: Rehabilitation / Physical Therapy
Article Date: 21 Mar 2011 - 13:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
4 starsnot yet rated
Patients with facial paralysis who underwent surgical treatment for a condition that leaves them unable to completely close their eyes reported improvement in comfort around the eyes and overall quality of life, according to a report in the March issue of Archives of Facial Plastic Surgery, one of the JAMA/Archives journals.

The inability to close the eye can be a devastating result of facial paralysis. "The resulting loss of corneal protection can lead to exposure keratitis [inflammation of the cornea], corneal ulceration, and potentially permanently vision loss," the authors write as background information in the article. "Eyelid weight placement, lower eyelid suspension, and brow ptosis [drooping or sagging of the eyelid] correction are frequently performed to protect the eye."

Douglas K. Henstrom, M.D., of Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, and colleagues measured and reported the change in quality of life (QOL) after surgical periocular treatment. The researchers used the Facial Clinimetric Evaluation (FaCE) scale - a patient-based system that measures impairment and disability in facial paralysis and represents a valuable adjunct to traditional physician-graded scales for evaluating QOL issues in patients affected by facial paralysis.

From March 2009 to May 2010, 49 patients with paralytic inability to completely close the eye were treated at the Facial Nerve Center at Massachusetts Eye and Ear Infirmary, Boston. Thirty-seven of the patients completed preoperative and postoperative FaCE surveys.

"Overall QOL, measured by the FaCE instrument, significantly improved following static periocular treatment," the authors report. "Mean FaCE scores increased from 44.1 to 52.7."

"Patients also reported a significant decrease in the amount of time their eye felt dry, irritated, or scratchy," the authors write.

Two patients experienced localized cellulitis (a bacterial infection of the skin and tissues beneath the skin) in reaction to the eyelid weight. There was one eyelid weight extrusion.

"In the overall treatment paradigm for patients with facial paralysis, treating the eye using this modality is simple, and not only improves corneal protection but also yields a significant subjective benefit," the authors conclude.

Arch Facial Plast Surg. 2011;13[2]:125-128.

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Thursday, April 7, 2011

Stroke Incidence Higher Among Patients With Certain Type Of Retinal Vascular Disease


Academic Journal
Main Category: Eye Health / Blindness
Also Included In: Vascular;  Stroke
Article Date: 14 Mar 2011 - 13:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
4 starsnot yet rated
Patients with a disease known as retinal vein occlusion (RVO) have a significantly higher incidence of stroke when compared with persons who do not have RVO, according to a report in the March issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

"Retinal vein occlusion (RVO) is a retinal vascular disease in which a retinal vein is compressed by an adjacent retinal artery, resulting in blood flow turbulence, thrombus formation, and retinal ischemia," the authors write as background information in the article. "Although RVO is a significant cause of severe visual impairment in adults, it can occur at any age." Older age, diabetes, hypertension and vascular disease are among the risk factors for RVO.

Winifred Werther, Ph.D., then of Genentech Inc., South San Francisco, Calif., now of Vertex Pharmaceuticals, Cambridge, Mass., and colleagues conducted a retrospective cohort study to compare the incidence rates of myocardial infarction (MI, heart attack) and cerebrovascular accident (CVA, stroke) in hospitalized patients with and without retinal vein occlusion. The researchers used a U.S. population-based health care claims database to identify patients with RVO and control patients, matched for age and sex.

Among 4,500 patients with RVO and 13,500 control patients, the researchers found that patients with RVO had an almost two-fold higher incidence of stroke than the age- and sex-matched controls.

"Event rates for CVA were 1.16 and 0.52 per 100 person-years for RVO and controls, respectively," the authors report.

In contrast, event rates for heart attack were similar in the patients with RVO and the control patients.

"Although men and patients younger than 65 years with RVO had a 1.6- and 1.9-fold higher risk of MI, respectively, compared with controls, there were no statistically significant differences in MI rates between patients with RVO and controls when they were stratified by sex or age," the authors write.

They conclude that "these data suggest that physicians and patients should be aware of the possible increased risk of CVA but not of MI in patients with RVO."

Arch Ophthalmol , 2011;129[3]:326-331.

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

ORange Wavefront Aberrometer Proves Successful In Determining Refraction In Cataract Patients Who Previously Had LASIK Surgery


Main Category: Eye Health / Blindness
Also Included In: Medical Devices / Diagnostics
Article Date: 21 Mar 2011 - 4:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
not yet ratednot yet rated
WaveTec Vision, the leader in wavefront-guided custom cataract™ surgery, announced today that its ORange® intraoperative wavefront aberrometer has been shown to be more predictable in determining refraction in the post-refractive eye, than any other post-LASIK formula currently available.

"Following LASIK, patients expect a lifetime of quality uncorrected vision. Unfortunately, these same patients are the most difficult to predict the optimal IOL power when they develop cataracts"

Wavefront custom cataract aberrometry with ORange is a breakthrough in modern cataract surgery. The technology has been clinically proven to increase accuracy and improve refractive outcomes: 73 percent of procedures are within 0.5D of intended target, versus 58 percent with traditional cataract surgery using standard method biometry.

"Following LASIK, patients expect a lifetime of quality uncorrected vision. Unfortunately, these same patients are the most difficult to predict the optimal IOL power when they develop cataracts," Eric Donnenfeld, MD said. "WaveTec's ORange, in my experience and now documented in studies, is the best technology to improve refractive outcomes and overall patient satisfaction in post LASIK eyes."

A patented diagnostic breakthrough, ORange allows cataract surgeons - for the first time - to measure refraction during surgery, so they can precisely predict and customize how their patients will see following the procedure.

The new post-LASIK coefficients which are part of the recently released ORange v2.6 software upgrade, will greatly improve post operative cataract refractive outcomes for patients having undergone previous corneal refractive surgery.

Source:
WaveTec Vision

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Tuesday, March 29, 2011

ORange Wavefront Aberrometer Proves Successful In Determining Refraction In Cataract Patients Who Previously Had LASIK Surgery


Main Category: Eye Health / Blindness
Also Included In: Medical Devices / Diagnostics
Article Date: 21 Mar 2011 - 4:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
not yet ratednot yet rated
WaveTec Vision, the leader in wavefront-guided custom cataract™ surgery, announced today that its ORange® intraoperative wavefront aberrometer has been shown to be more predictable in determining refraction in the post-refractive eye, than any other post-LASIK formula currently available.

"Following LASIK, patients expect a lifetime of quality uncorrected vision. Unfortunately, these same patients are the most difficult to predict the optimal IOL power when they develop cataracts"

Wavefront custom cataract aberrometry with ORange is a breakthrough in modern cataract surgery. The technology has been clinically proven to increase accuracy and improve refractive outcomes: 73 percent of procedures are within 0.5D of intended target, versus 58 percent with traditional cataract surgery using standard method biometry.

"Following LASIK, patients expect a lifetime of quality uncorrected vision. Unfortunately, these same patients are the most difficult to predict the optimal IOL power when they develop cataracts," Eric Donnenfeld, MD said. "WaveTec's ORange, in my experience and now documented in studies, is the best technology to improve refractive outcomes and overall patient satisfaction in post LASIK eyes."

A patented diagnostic breakthrough, ORange allows cataract surgeons - for the first time - to measure refraction during surgery, so they can precisely predict and customize how their patients will see following the procedure.

The new post-LASIK coefficients which are part of the recently released ORange v2.6 software upgrade, will greatly improve post operative cataract refractive outcomes for patients having undergone previous corneal refractive surgery.

Source:
WaveTec Vision

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Sunday, March 27, 2011

Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial For Treatment Of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma


Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Clinical Trials / Drug Trials;  Blood / Hematology;  Cancer / Oncology
Article Date: 21 Mar 2011 - 2:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
3 starsnot yet rated
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has initiated its randomized pivotal trial of pixantrone for the treatment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL"). The clinical trial is now open to patient enrollment. The trial, referred to as the PIX-R or PIX 306 trial, will compare a combination of pixantrone plus rituximab to a combination of gemcitabine plus rituximab in patients with relapsed or refractory DLBCL who have received one to three prior lines of therapy. The PIX-R trial utilizes progression free survival ("PFS") and overall survival ("OS") as co-primary endpoints of the study. The PIX-R trial is targeting to enroll approximately 350 patients over 18 months and will include patients who have failed at least one line of previous therapy and patients who are not candidates for myeloablative chemotherapy and stem cell transplant.

"We are pleased to open enrollment for this study and have been in communication with leading cancer clinical sites that are enthusiastic about participating in the study largely based on the positive results of our previous study, PIX301, in relapsed/refractory aggressive non-Hodgkin's lymphoma patients," said Jack W. Singer, M.D., Chief Medical Officer of CTI. "There is an unmet medical need in this patient group, and the lack of any FDA approved drug for these patients should generate strong interest in the trial from both the patients and physicians."

For more information on the PIX-R trial, investigators and patients can visit here. CTI expects the PIX-R trial to be posted to clinicaltrials.gov in the near future. CTI expects to have 60 sites open for enrollment by the end of April 2011.

The PIX-R trial may serve as either a post-marketing commitment trial or as a follow-on pivotal trial depending on the outcome of a formal appeal that CTI submitted to the Food & Drug Administration's (the "FDA") Office of New Drugs in the FDA's Center for Drug Evaluation and Research in December 2010 regarding its 2010 decision about CTI's new drug application (the "NDA") for pixantrone. The NDA for pixantrone was based on the results of the PIX 301 trial, a randomized trial comparing pixantrone as monotherapy to a choice of standard single-agent chemotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") patients. CTI expects a decision regarding its appeal in the second quarter of 2011.

PIX-R TRIAL Design

The PIX-R trial is designed to be a randomized, multicenter study comparing pixantrone plus rituximab to gemcitabine plus rituximab in patients with relapsed or refractory DLBCL or DLBCL transformed from follicular lymphoma who have received one to three prior lines of therapy, including CHOP-R or an equivalent regimen. The patients to be enrolled in the PIX-R trial cannot be eligible for high-dose (myeloablative) chemotherapy and stem cell transplant, but patients who relapse after such a procedure are eligible. The co-primary endpoints for the PIX-R trial are PFS and OS with secondary endpoints including overall response rate ("ORR") (ORR equals complete responses plus partial responses), complete response rate and safety. CTI is targeting to enroll 350 patients over 18 months in the PIX-R trial.

About Pixantrone

Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II, but unlike anthracyclines, rather than intercalation with DNA, pixantrone alkylates DNA and forms stable DNA adducts with particular specificity for CpG rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone to prevent the binding of iron and perpetuation of superoxide production--both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory diffuse large lymphoma without unacceptable rates of cardiotoxicity.

Source:
Cell Therapeutics, Inc.


Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here